Seattle, WA, United States of America

Betty A Haldeman

USPTO Granted Patents = 23 


Average Co-Inventor Count = 3.4

ph-index = 11

Forward Citations = 314(Granted Patents)


Company Filing History:


Years Active: 2003-2013

Loading Chart...
Loading Chart...
23 patents (USPTO):Explore Patents

Title: Innovations by Betty A Haldeman: Pioneering Antibody Research

Introduction

Betty A Haldeman, based in Seattle, WA, is a notable inventor with an impressive portfolio of 23 patents. Her work primarily focuses on antibody research and its applications in the medical field, particularly concerning wound healing and platelet proliferation.

Latest Patents

Among her latest patents is the innovative "Antibody to human zcyto-10 polypeptide." This patent describes antibodies that specifically bind to a mammalian cytokine-like polypeptide known as Zcyto10. The innovation includes monoclonal antibodies and antigen-binding fragments. The significance of Zcyto10 lies in its utility in promoting the healing of wounds and stimulating the proliferation of platelets. Another recent patent, also related to Zcyto10, includes polynucleotides encoding the polypeptide, antibodies that specifically bind to it, and anti-idiotypic antibodies targeting the antibodies themselves. These advancements showcase Haldeman's contributions to biotechnological innovations.

Career Highlights

Betty A Haldeman currently works at Zymogenetics, Inc., where she continues to advance her research and develop new technologies. Her career reflects a deep commitment to improving health outcomes through innovative antibody-based therapies.

Collaborations

Haldeman collaborates with notable colleagues such as Paul O. Sheppard and Darrell C. Conklin, enhancing her research efforts. These collaborations underscore the importance of teamwork in scientific discovery and innovation.

Conclusion

Betty A Haldeman's contributions to the field of antibody research exemplify the power of innovation in medicine. With a robust patent portfolio and a focus on practical applications, her work promises to impact wound healing and platelet proliferation significantly. Her ongoing research at Zymogenetics, Inc. continues to push the boundaries of what is possible in therapeutic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…